Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00381147
Other study ID # S-340-14-6-1-PU-11
Secondary ID
Status Completed
Phase Phase 3
First received September 26, 2006
Last updated January 6, 2009

Study information

Verified date September 2006
Source Baqiyatallah Medical Sciences University
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- His/her own will to participate

- Documented chemical exposure

- Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)

Exclusion Criteria:

- any drug reactions during the trial

- history of sensitivity to macrolides

- diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis, dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural changes, early fatigue, odynophagia, glossitis , dizziness

- co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine, dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any immunosuppressive, any systemic antibiotics

- using drugs that he/she cannot discontinue

- using drugs with potential interaction

- subject will to exit from the trial

- history of lobe resection of lung

- history of exacerbation in the last month prior to the beginning of trial

- continuous need to oxygen

- use of corticosteroids in last week prior to the trial beginning

- Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic

- exacerbating of subjects

- creatinine srum level more than normal

- increasing ALT, AST levels

- total bilirubin more twice than normal

- subjects who did not use their drugs properly

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Clarithromycin


Locations

Country Name City State
Iran, Islamic Republic of Baqiyatallah Medical Sciences University Tehran

Sponsors (1)

Lead Sponsor Collaborator
Baqiyatallah Medical Sciences University

Country where clinical trial is conducted

Iran, Islamic Republic of, 

See also
  Status Clinical Trial Phase
Recruiting NCT03603899 - Hp129 Xenon Imaging and BOS in Lung Transplantation Phase 1/Phase 2
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT02543073 - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Phase 1/Phase 2
Terminated NCT01432080 - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Phase 2
Recruiting NCT00163696 - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease N/A
Completed NCT00029328 - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Phase 1/Phase 2
Terminated NCT01163786 - A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Phase 2
Recruiting NCT02627833 - Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO N/A
Completed NCT01212406 - Vitamin D in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT01211509 - Montelukast in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Completed NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Phase 2
Recruiting NCT05922761 - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Phase 2
Recruiting NCT05881538 - High Intensity Intervallic Training in Children With Bronchiolitis Obliterans N/A
Terminated NCT04655508 - Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Phase 3
Withdrawn NCT02109237 - Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3 N/A
Completed NCT01327248 - Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans N/A
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3